ReviewArthritis care & research2020
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
Review in Arthritis care & research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Early and late RNA eQTL are driven by different genetic mechanisms.Nature communications · 2026Article
- A population-scale atlas of blood and tissue in lupus nephritis.bioRxiv : the preprint server for biology · 2026Article
- Mapping the circulating proteome across neurodegeneration: A harmonized, consortium-scale framework for uncovering molecular pathophysiology.bioRxiv : the preprint server for biology · 2025Article
- Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.Rheumatology (Oxford, England) · 2025Article
- Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells.Science translational medicine · 2024Article
- Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Pseudo-spectral angle mapping for pixel and cell classification in highly multiplexed immunofluorescence images.Journal of medical imaging (Bellingham, Wash.) · 2024Article
- Precision Medicine in Nephrology: An Integrative Framework of Multidimensional Data in the Kidney Precision Medicine Project.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Article
- Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.Arthritis research & therapy · 2024Article
- Pseudo-spectral angle mapping for automated pixel-level analysis of highly multiplexed tissue image data.bioRxiv : the preprint server for biology · 2024Article
- Urinary biomarkers associated with podocyte injury in lupus nephritis.Frontiers in pharmacology · 2024Review
- Kidney and urine cell transcriptomics in IgA nephropathy and lupus nephritis: a narrative review.Clinical kidney journal · 2024Review
- Single cell spatial transcriptomic profiling of childhood-onset lupus nephritis reveals complex interactions between kidney stroma and infiltrating immune cells.bioRxiv : the preprint server for biology · 2023Article
- A Strategic Research Framework for Defeating Diabetes in India: A 21st-Century Agenda.Journal of the Indian Institute of Science · 2023Review
- Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Cellular and molecular interrogation of kidney biopsy specimens.Current opinion in nephrology and hypertension · 2022Review
- Urine Single-Cell RNA Sequencing in Focal Segmental Glomerulosclerosis Reveals Inflammatory Signatures.Kidney international reports · 2022Article
- Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.Lupus science & medicine · 2021Article
- Renal Mononuclear Phagocytes in Lupus Nephritis.ACR open rheumatology · 2021Review
- The basic and translational science year in review: Confucius in the era of Big Data.Seminars in arthritis and rheumatism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers to apply high-throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for analysis of a large cohort of LN samples in phase 2 and provides a model for establishing similar discovery cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.